Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30049
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWei, Gavin-
dc.contributor.authorKelly, Brian D-
dc.contributor.authorTimm, Brennan-
dc.contributor.authorPerera, Marlon-
dc.contributor.authorLundon, D J-
dc.contributor.authorJack, Gregory S-
dc.contributor.authorBolton, Damien M-
dc.date2021-
dc.date.accessioned2022-06-22T06:51:15Z-
dc.date.available2022-06-22T06:51:15Z-
dc.date.issued2021-05-
dc.identifier.citationBJUI Compass 2021; 2(3): 194-201en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/30049-
dc.description.abstractTo compare the accuracy of the European Randomized Study of Screening for Prostate Cancer (ERSPC) RC, MRI-ERSPC-RC, and Prostate Biopsy Collaborative Group (PBCG) RC in patients undergoing transperineal prostate biopsy. We identified 392 patients who underwent mpMRI before transperineal prostate biopsy across multiple public and private institutions between January 2017 and August 2019. The estimated probabilities of detecting PCa and significant PCa were calculated using the MRI-ERSPC-RC, ERSPC-RC, and PBCG-RC. Receiver operating characteristic (ROC) curves for each calculator were generated and the area underneath the curve (AUC) was compared. Calibration and clinical utility were assessed with calibration plots and decision curve analysis, respectively. PCa was detected in 285 patients (72.7%) with significant PCa found in 200 patients (51.1%). ROC curve analysis found the MRI-ERSPC-RC outperformed the ERSPC-RC and PBCG-RC. For the prediction of PCa, the AUC was 0.756, 0.696, and 0.675 for the MRI-ERSPC-RC, ERSPC-RC, and PBCG-RC, respectively. The AUC for the prediction of significant PCa was 0.803, 0.745, and 0.746 for the MRI-ERSPC-RC, ERSPC-RC, and PBCG-RC, respectively. Our study validated the ERSPC-RC, MRI-ERSPC-RC, and PBCG-RC in a cohort undergoing transperineal prostate biopsy with the MRI-ERSPC-RC performing the best. These RCs may enable improved shared decision making and help to guide patient selection for biopsy.en
dc.language.isoeng
dc.subjectERSPCen
dc.subjectPBCGen
dc.subjectbiopsyen
dc.subjectmag nomogramen
dc.subjectnetic resonance imagingen
dc.subjectprostate canceren
dc.titleClash of the calculators: External validation of prostate cancer risk calculators in men undergoing mpMRI and transperineal biopsy.en
dc.typeJournal Articleen
dc.identifier.journaltitleBJUI Compassen
dc.identifier.affiliationOlivia Newton-John Cancer Wellness and Research Centreen
dc.identifier.affiliationSurgery (University of Melbourne)en
dc.identifier.affiliationNorth Eastern Urology Melbourne VIC Australiaen
dc.identifier.affiliationDepartment of Urology Icahn School of Medicine Mount Sinai Hospitals New York NY USAen
dc.identifier.affiliationFaculty of Medicine University of Queensland Brisbane QLD Australiaen
dc.identifier.doi10.1002/bco2.58en
dc.type.contentTexten
dc.identifier.orcidhttps://orcid.org/0000-0001-5168-6346en
dc.identifier.orcidhttps://orcid.org/0000-0001-9554-3953en
dc.identifier.orcidhttps://orcid.org/0000-0001-6195-3364en
dc.identifier.orcidhttps://orcid.org/0000-0002-1138-6389en
dc.identifier.orcidhttps://orcid.org/0000-0002-5145-6783en
dc.identifier.orcidhttps://orcid.org/0000-0001-9192-8362en
dc.identifier.pubmedid35475133
local.name.researcherBolton, Damien M
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptSurgery (University of Melbourne)-
crisitem.author.deptUrology-
crisitem.author.deptUrology-
crisitem.author.deptSurgery-
crisitem.author.deptUrology-
crisitem.author.deptUrology-
crisitem.author.deptUrology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

26
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.